{"artifact":{"id":"open_question-9f118a5b-0d02-423a-a8ed-2e5c1c8843aa","artifact_type":"open_question","entity_ids":"[\"diseases\"]","title":"What combinations of molecular and digital biomarkers should become standard in platform trials?","quality_score":0.5,"created_by":"backfill_open_questions","provenance_chain":"[]","content_hash":"8153c59832ad19ac69c7597dd3b3a244e8120f4ba99a61621724cccb060de9a9","metadata":{"status":"open","_origin":{"url":null,"type":"internal","tracked_at":"2026-04-26T03:29:12.201677"},"field_tag":"diseases","source_id":"diseases-als-progression-rate-heterogeneity","sub_field":"als-progression-rate-heterogeneity","source_kind":"wiki","question_hash":"ac3a6b89ca8e4e0ee59c2559b72e195345b1e24606f7b26074a820333b593406","question_text":"What combinations of molecular and digital biomarkers should become standard in platform trials?","importance_elo":1500,"_schema_version":1,"evidence_summary":"Extracted from wiki page diseases-als-progression-rate-heterogeneity","tractability_score":0.5,"potential_impact_score":0.5},"created_at":"2026-04-25T20:29:12.201776-07:00","updated_at":"2026-04-25T20:29:12.201776-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-25T20:29:12.201776-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"2f352420-fe6c-422b-82fd-c2fa6b8d82fb","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"backfill_open_questions"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"wiki-diseases-als-progression-rate-heterogeneity","link_type":"derives_from","strength":0.9,"evidence":"{\"method\": \"open_question_wiki_crosslink\", \"cycle\": \"artifact-enrichment-2026-04-27\"}"}],"incoming_links":[],"current_artifact_id":"open_question-9f118a5b-0d02-423a-a8ed-2e5c1c8843aa","is_canonical":true,"supersede_chain":["open_question-9f118a5b-0d02-423a-a8ed-2e5c1c8843aa"]}